{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:30:55Z","timestamp":1787959855158,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ruth L. Kirschstein National Research Service Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1245\/s10434-023-13475-7","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T12:02:36Z","timestamp":1684497756000},"page":"5610-5618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Axillary Lymph Node Dissection is Associated with Improved Survival Among Men with Invasive Breast Cancer and Sentinel Node Metastasis"],"prefix":"10.1245","volume":"30","author":[{"given":"Sophie H.","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna W. L.","family":"de Geus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Shewmaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey S.","family":"Romatoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick T.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi Y.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel E.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer F.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teviah E.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0522-8667","authenticated-orcid":false,"given":"Michael R.","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"13475_CR1","unstructured":"Centers for Disease Control and Prevention. Male breast cancer incidence and mortality, United States\u20142013\u20132017. USCS Data Brief, no 19. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services. 2020. https:\/\/www.cdc.gov\/cancer\/uscs\/about\/data-briefs\/no19-male-breast-cancer-incidence-mortality-UnitedStates-2013-2017.htm."},{"issue":"6","key":"13475_CR2","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1177\/1557988318799025","volume":"12","author":"E Midding","year":"2018","unstructured":"Midding E, Halbach SM, Kowalski C, Weber R, W\u00fcrstlein R, Ernstmann N. Men with a \u201cwoman\u2019s disease\u201d: stigmatization of male breast cancer patients-a mixed methods analysis. Am J Mens Health. 2018;12(6):2194\u2013207. https:\/\/doi.org\/10.1177\/1557988318799025.","journal-title":"Am J Mens Health"},{"issue":"1","key":"13475_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","journal-title":"CA Cancer J Clin"},{"key":"13475_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1477-7819-6-58","volume":"6","author":"KB Contractor","year":"2008","unstructured":"Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol. 2008;6:58. https:\/\/doi.org\/10.1186\/1477-7819-6-58.","journal-title":"World J Surg Oncol"},{"issue":"12","key":"13475_CR5","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1245\/s10434-020-08901-z","volume":"27","author":"JK Plichta","year":"2020","unstructured":"Plichta JK, Ren Y, Marks CE, et al. Surgery for men with breast cancer: do the same data still apply? Ann Surg Oncol. 2020;27(12):4720\u20139. https:\/\/doi.org\/10.1245\/s10434-020-08901-z.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"13475_CR6","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.1634\/theoncologist.2019-0871","volume":"25","author":"KL Corrigan","year":"2020","unstructured":"Corrigan KL, Mainwaring W, Miller AB, et al. Exclusion of men from randomized phase III breast cancer clinical trials. Oncologist. 2020;25(6):e990\u20132. https:\/\/doi.org\/10.1634\/theoncologist.2019-0871.","journal-title":"Oncologist"},{"issue":"16","key":"13475_CR7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1200\/JCO.19.03120","volume":"38","author":"MJ Hassett","year":"2020","unstructured":"Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol. 2020;38(16):1849\u201363. https:\/\/doi.org\/10.1200\/JCO.19.03120.","journal-title":"J Clin Oncol"},{"issue":"9","key":"13475_CR8","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/bjs\/znab279","volume":"108","author":"AP Lin","year":"2021","unstructured":"Lin AP, Huang T-W, Tam K-W. Treatment of male breast cancer: meta-analysis of real-world evidence. Br J Surg. 2021;108(9):1034\u201342. https:\/\/doi.org\/10.1093\/bjs\/znab279.","journal-title":"Br J Surg"},{"issue":"6","key":"13475_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375. https:\/\/doi.org\/10.1001\/jama.2011.90.","journal-title":"JAMA"},{"issue":"12","key":"13475_CR10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol"},{"issue":"2","key":"13475_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdx651","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405\u201317. https:\/\/doi.org\/10.1093\/annonc\/mdx651.","journal-title":"Ann Oncol"},{"issue":"2","key":"13475_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12032-011-9978-9","volume":"29","author":"UY Arslan","year":"2012","unstructured":"Arslan UY, Oksuzoglu B, Ozdemir N, et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012;29(2):554\u201360. https:\/\/doi.org\/10.1007\/s12032-011-9978-9.","journal-title":"Med Oncol"},{"key":"13475_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/bctt.S6519","volume":"2","author":"L Ottini","year":"2010","unstructured":"Ottini L, Capalbo C, Rizzolo P, et al. HER2-positive male breast cancer: an update. Breast Cancer (Dove Med Press). 2010;2:45\u201358. https:\/\/doi.org\/10.2147\/bctt.S6519.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"2","key":"13475_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/jco.2009.23.8162","volume":"28","author":"WF Anderson","year":"2010","unstructured":"Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232\u20139. https:\/\/doi.org\/10.1200\/jco.2009.23.8162.","journal-title":"J Clin Oncol"},{"issue":"8","key":"13475_CR15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/cncr.22589","volume":"109","author":"ZA Nahleh","year":"2007","unstructured":"Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer. 2007;109(8):1471\u20137. https:\/\/doi.org\/10.1002\/cncr.22589.","journal-title":"Cancer"},{"issue":"1","key":"13475_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-018-4921-9","volume":"173","author":"A Gucalp","year":"2019","unstructured":"Gucalp A, Traina TA, Eisner JR, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019;173(1):37\u201348. https:\/\/doi.org\/10.1007\/s10549-018-4921-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"13475_CR17","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-15-2840","volume":"22","author":"S Piscuoglio","year":"2016","unstructured":"Piscuoglio S, Ng CK, Murray MP, et al. The genomic landscape of male breast cancers. Clin Cancer Res. 2016;22(16):4045\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2840.","journal-title":"Clin Cancer Res"},{"key":"13475_CR18","unstructured":"Data from: National Cancer Data Base."},{"issue":"2","key":"13475_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-019-05243-7","volume":"176","author":"A Weiss","year":"2019","unstructured":"Weiss A, Lin H, Babiera GV, et al. Evolution in practice patterns of axillary management following mastectomy in patients with 1\u20132 positive sentinel nodes. Breast Cancer Res Treat. 2019;176(2):435\u201344. https:\/\/doi.org\/10.1007\/s10549-019-05243-7.","journal-title":"Breast Cancer Res Treat"},{"key":"13475_CR20","unstructured":"The PSMATCH Procedure. SAS Institute Inc. https:\/\/documentation.sas.com\/doc\/en\/statug\/15.2\/statug_psmatch_toc.htm. Accessed Oct 28, 2020."},{"issue":"4","key":"13475_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00423-003-0410-6","volume":"388","author":"E Bollschweiler","year":"2003","unstructured":"Bollschweiler E. Benefits and limitations of Kaplan\u2013Meier calculations of survival chance in cancer surgery. Langenbecks Arch Surg. 2003;388(4):239\u201344. https:\/\/doi.org\/10.1007\/s00423-003-0410-6.","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"13475_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cncr.32472","volume":"126","author":"S Yadav","year":"2020","unstructured":"Yadav S, Karam D, Bin Riaz I, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer. 2020;126(1):26\u201336. https:\/\/doi.org\/10.1002\/cncr.32472.","journal-title":"Cancer"},{"issue":"7","key":"13475_CR23","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1245\/s10434-014-3595-8","volume":"21","author":"SH Javid","year":"2014","unstructured":"Javid SH, He H, Korde LA, Flum DR, Anderson BO. Predictors and outcomes of completion axillary node dissection among older breast cancer patients. Ann Surg Oncol. 2014;21(7):2172\u201380. https:\/\/doi.org\/10.1245\/s10434-014-3595-8.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"13475_CR24","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/cncr.21526","volume":"104","author":"SH Giordano","year":"2005","unstructured":"Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104(11):2359\u201364. https:\/\/doi.org\/10.1002\/cncr.21526.","journal-title":"Cancer"},{"issue":"5","key":"13475_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.clbc.2013.05.004","volume":"13","author":"S Fogh","year":"2013","unstructured":"Fogh S, Kachnic LA, Goldberg SI, Taghian AG, Powell SN, Hirsch AE. Localized therapy for male breast cancer: functional advantages with comparable outcomes using breast conservation. Clin Breast Cancer. 2013;13(5):344\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2013.05.004.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"13475_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3816\/CBC.2011.n.007","volume":"11","author":"S Fogh","year":"2011","unstructured":"Fogh S, Hirsch AE, Langmead JP, et al. Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. Clin Breast Cancer. 2011;11(1):39\u201345. https:\/\/doi.org\/10.3816\/CBC.2011.n.007.","journal-title":"Clin Breast Cancer"},{"key":"13475_CR27","unstructured":"American Cancer Society. Breast Cancer Facts & Figures 2019\u20132020. Atlanta: American Cancer Society, Inc. 2019. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2019-2020.pdf."},{"issue":"3","key":"13475_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10549-018-4952-2","volume":"172","author":"IS Fentiman","year":"2018","unstructured":"Fentiman IS. Surgical options for male breast cancer. Breast Cancer Res Treat. 2018;172(3):539\u201344. https:\/\/doi.org\/10.1007\/s10549-018-4952-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"13475_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamaoncol.2020.7442","volume":"7","author":"M Reinisch","year":"2021","unstructured":"Reinisch M, Seiler S, Hauzenberger T, et al. Efficacy of endocrine therapy for the treatment of breast cancer in men: results from the MALE Phase 2 randomized clinical trial. JAMA Oncol. 2021;7(4):565\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7442.","journal-title":"JAMA Oncol"},{"issue":"10","key":"13475_CR30","doi-asserted-by":"publisher","first-page":"e181114","DOI":"10.1001\/jamaoncol.2018.1114","volume":"4","author":"S Venigalla","year":"2018","unstructured":"Venigalla S, Carmona R, Guttmann DM, et al. Use and effectiveness of adjuvant endocrine therapy for hormone receptor-positive breast cancer in men. JAMA Oncol. 2018;4(10):e181114. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1114.","journal-title":"JAMA Oncol"},{"issue":"3","key":"13475_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-022-06536-0","volume":"192","author":"A Ali","year":"2022","unstructured":"Ali A, Xie Z, Stanko L, et al. Endocrine adherence in male versus female breast cancer: a seer-medicare review. Breast Cancer Res Treat. 2022;192(3):491\u20139. https:\/\/doi.org\/10.1007\/s10549-022-06536-0.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"13475_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3747\/co.v17i5.631","volume":"17","author":"H Visram","year":"2010","unstructured":"Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010;17(5):17\u201321. https:\/\/doi.org\/10.3747\/co.v17i5.631.","journal-title":"Curr Oncol"},{"key":"13475_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10549-006-9356-z","volume":"103","author":"A Agrawal","year":"2007","unstructured":"Agrawal A, Ayantunde A, Rampaul R, Robertson J. Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2007;103:11\u201321.","journal-title":"Breast Cancer Res Treat"},{"key":"13475_CR34","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","volume":"378","author":"S Darby","year":"2011","unstructured":"Darby S, McGale P, Correa CF, Shao Y, Swain S, Taylor C, Valagussa P, Viale G, Whelan T, Winer E, Wang Y, Wood W. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707\u201316.","journal-title":"Lancet"},{"key":"13475_CR35","volume-title":"Diseases of the breast","author":"JR Harris","year":"2012","unstructured":"Harris JR, Lippman ME, Osborne CK, Morrow M. Diseases of the breast. Lippincott Williams & Wilkins; 2012."},{"key":"13475_CR36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1245\/s10434-007-9709-9","volume":"15","author":"H Suami","year":"2008","unstructured":"Suami H, Pan W-R, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol. 2008;15:863\u201371.","journal-title":"Ann Surg Oncol"},{"key":"13475_CR37","first-page":"411","volume":"2012","author":"O Schmetzer","year":"2012","unstructured":"Schmetzer O, Fl\u00f6rcken A. Sex differences in the drug therapy for oncologic diseases. Sex Gend Differ Pharmacol. 2012;2012:411\u201342.","journal-title":"Sex Gend Differ Pharmacol"},{"key":"13475_CR38","first-page":"91","volume":"2012","author":"I Spoletini","year":"2012","unstructured":"Spoletini I, Vitale C, Malorni W, Rosano GM. Sex differences in drug effects: interaction with sex hormones in adult life. Sex Gend Differ Pharmacol. 2012;2012:91\u2013105.","journal-title":"Sex Gend Differ Pharmacol"},{"issue":"2","key":"13475_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mds283","volume":"24","author":"C Vaysse","year":"2013","unstructured":"Vaysse C, Sroussi J, Mallon P, et al. Prediction of axillary lymph node status in male breast carcinoma. Ann Oncol. 2013;24(2):370\u20136. https:\/\/doi.org\/10.1093\/annonc\/mds283.","journal-title":"Ann Oncol"},{"issue":"1","key":"13475_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/cncr.33899","volume":"128","author":"O Oke","year":"2022","unstructured":"Oke O, Niu J, Chavez-MacGregor M, Zhao H, Giordano SH. Adjuvant tamoxifen adherence in men with early-stage breast cancer. Cancer. 2022;128(1):59\u201364. https:\/\/doi.org\/10.1002\/cncr.33899.","journal-title":"Cancer"},{"issue":"1","key":"13475_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/1097-0142(19940701)74:1<74::aid-cncr2820740113>3.0.co;2-#","volume":"74","author":"TF Anelli","year":"1994","unstructured":"Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer. 1994;74(1):74\u20137. https:\/\/doi.org\/10.1002\/1097-0142(19940701)74:1%3c74::aid-cncr2820740113%3e3.0.co;2-#.","journal-title":"Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13475-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13475-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13475-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T13:05:22Z","timestamp":1691499922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13475-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["13475"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13475-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}